Picton Mahoney Asset Management Raises Stock Position in Gilead Sciences, Inc. $GILD

Picton Mahoney Asset Management lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 340,085.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,626 shares of the biopharmaceutical company’s stock after buying an additional 47,612 shares during the period. Picton Mahoney Asset Management’s holdings in Gilead Sciences were worth $5,287,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in GILD. Level Four Advisory Services LLC increased its stake in Gilead Sciences by 2.2% during the third quarter. Level Four Advisory Services LLC now owns 26,910 shares of the biopharmaceutical company’s stock worth $2,987,000 after acquiring an additional 585 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Gilead Sciences by 1.8% in the 3rd quarter. Victory Capital Management Inc. now owns 2,841,094 shares of the biopharmaceutical company’s stock worth $315,361,000 after purchasing an additional 50,955 shares during the period. 111 Capital increased its position in shares of Gilead Sciences by 9.3% during the 3rd quarter. 111 Capital now owns 25,037 shares of the biopharmaceutical company’s stock valued at $2,779,000 after purchasing an additional 2,129 shares during the last quarter. Elo Mutual Pension Insurance Co raised its holdings in Gilead Sciences by 3.1% during the 3rd quarter. Elo Mutual Pension Insurance Co now owns 165,116 shares of the biopharmaceutical company’s stock valued at $18,328,000 after buying an additional 5,038 shares during the period. Finally, Staley Capital Advisers Inc. purchased a new stake in Gilead Sciences during the 3rd quarter valued at $222,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Scotiabank increased their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 11th. HSBC raised their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Finally, Mizuho upped their target price on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Twenty-three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $156.72.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the sale, the chief executive officer owned 566,698 shares in the company, valued at $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the sale, the insider directly owned 120,288 shares in the company, valued at $18,577,278.72. This trade represents a 18.88% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 309,280 shares of company stock worth $43,935,470. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

GILD stock opened at $148.22 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The business has a 50-day moving average price of $137.52 and a 200 day moving average price of $125.43. The company has a market capitalization of $184.00 billion, a P/E ratio of 21.89, a PEG ratio of 1.94 and a beta of 0.37. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio is 46.68%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.